BSE · 532039
Zenotech Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹11 Cr with net profit ₹-0 Cr — a -4.34% net margin, versus -31.88% the period before.
Shareholding
As of 2026-06-30
- Promoter68.84%
- Public31.15%
- DII0.01%
10,161 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.64× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #23 of 50 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,429 Cr | 83.11 | 22.05 | 25.49% | 13.95% |
| Gland Pharma Limited | ₹47,982 Cr | 41.88 | 4.63 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹43,742 Cr | 38.54 | 9.66 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹29,437 Cr | 102.14 | 22.84 | 19.14% | 14.89% |
| Caplin Point Laboratories Ltd. | ₹19,737 Cr | 29.67 | 5.86 | 17.88% | 29.09% |
| Shilpa Medicare Ltd. | ₹18,744 Cr | 65.91 | 7.23 | 9.39% | 17.67% |
| Eris Lifesciences Limited | ₹18,164 Cr | 27.65 | 4.65 | 15.87% | 20.04% |
| Marksans Pharma Limited | ₹14,488 Cr | 28.04 | 4.79 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹7,344 Cr | 53.33 | 6.16 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,459 Cr | 51.12 | 6.92 | 12.36% | 18.59% |
| Zenotech Laboratories Ltd.(this company) | ₹275 Cr | — | 2.89 | -1.13% | -6.22% |
AI analysis
AI-generated · google/gemini-2.5-flashZenotech Laboratories Ltd. has a market capitalization of Rs 292 Cr. The company reported revenue of Rs 44.6 Cr. Its debt-to-equity ratio stands at 0.13.
Positives
- +The debt-to-equity ratio is low at 0.13.
- +Promoter shareholding is substantial at 68.8419%.
- +No promoter pledges have been reported.
Negatives
- −The company has a negative Return on Equity (ROE) of -112.7%.
- −The profit margin is significantly negative at -270.4%.
- −Earnings per share (EPS) is 0.
- −Quarterly net profit was negative Rs 3.15 Cr for March 2026.
Financial Performance
For the period ending March 2025, Zenotech Laboratories Ltd. reported revenue of Rs 44.5957 Cr and a net profit of Rs 5.6129 Cr. In the latest available quarterly results up to March 2026, revenue was Rs 9.88 Cr with a net loss of Rs 3.15 Cr.
Profitability & Returns
The company's Return on Capital Employed (ROCE) is 4.3584%. However, the Return on Equity (ROE) is -112.7%. The profit margin for the company is -270.4%.
Balance Sheet
Zenotech Laboratories Ltd. has a book value of Rs 15.59 per share. The debt-to-equity ratio is 0.13, indicating a low level of debt relative to equity.
Ownership & Pledges
There are no promoter pledges reported for the period ending June 2026.
Data as of — price: 2026-09-17 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Zenotech Laboratories Ltd.share price & fundamentals